|
nd polycystic kidney diseases, as well as cardiovascular diseases. In February this year, there was a press release about NNBP merging with Eureka Genomics. Here is the news. Nanobac Pharmaceuticals and Eureka Genomics Sign Merger Agreement 2010-02-17 07:58:45 Quote: NNBPNews) and privately held Eureka Genomics announced the signing of a definitive merger agreement, which delineates the terms and conditions under which Nanobac proposes to merge with Eureka in a stock and cash transaction.Under the terms of the agreement, Nanobac will issue new shares of its common stock to Eureka stockholders based on an exchange ratio to be determined prior to the closing of the transaction. Under the exchange ratio formula defined in the merger agreement, the former Eureka stockholders are expected to own 85 percent of the combined company, and the former Nanobac shareholders are expected to own 15 percent of the combined company, each on a fully diluted basis. This ratio is subject to potential adjustments as described in the merger agreement.The proposed merger would involve, among other things, a reverse stock split of shares in Nanobac Pharmaceuticals. When the merger is consummated, the Nanobac Pharmaceuticals name will be changed to Eureka Genomics Corp. The combined company intends to apply to change its ticker symbol on the OTC-Pink Sheets exchange. Subject to regulatory approvals and customary closing conditions, this merger is currently expected to close during the second quarter of 2009."We are excited about the opportunity to merge with a revenue-producing company that is well positioned to play a defining role in the evolution of high-value diagnostic tests and medicines, as well as cleantech products such as bioenergy feedstocks and bio-based industrial catalysts," said Dr. Benedict Maniscalco, Nanobac Pharmaceuticals Co-Chairman of the Board. "We firmly believe that this merger is the best step forward for Nanobac shareholders because it offers the potential to increase shareholder value.""We, too, are confident that this merger will help build shareholder value," said Eureka Genomics Chief Financial Officer and Chief Operating Officer Didier Perez. On March 10th this year, Eureka Genomics closed $3.7 million private fund financing. Here is the news: Eureka Genomics Closes $3.7 Million Private Financing HERCULES, CA (March 10, 2010): Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics' high-throughput sequencing and bioinformatics service business on a global basis. Eureka Genomics is an industry leader in the area of advanced bioinformatics analysis associated with next-generation sequencing data, and a provider of high-end services to diagnostics, pharmaceutical/biotechnology, agricultural and cleantech companies, as well as academic, public and private research laboratories. "This funding will support the advancement of our lead programs in colorectal cancer, lymphoma and cardiovascular disease," said Didier Perez, co-founder and Chief Operating Officer for Eureka Genomics. "Our advanced next-generation sequencing and bioinformatics capabilities have already resulted in the discovery of unique microbial associations with disease in animals and plants, and we are working to extend our discoveries to humans." He noted that since Eureka Genomics' founding in 2007, the company has formed a growing number of partnerships and collaborations with leading academic, governmental and private research organizations. "We intend to continue adding new partners over the coming year, including corporate collaborators for the co-development and commercialization of vaccines and diagnostics based on our discoveries." Eureka Genomics also plans to use the funds to help grow global sales and marketing for its high-end sequencing and bioinformatics business. "Over the course of our discovery research we have developed advanced capabilities in high-throughput sequencing and bioinformatics analysis that we leverage and bring to bear on our customers' everyday problems," said Heather Koshinsky, Ph.D., Eureka Genomics' co-founder and Chief Scientific Officer. "We have already gained widespread industry recognition as the leading provider of solutions to scientifically complex problems not addressable by other high-throughput sequencing and bioinformatics services. Our expertise and offerings ensure that Eureka Genomics' customers can quickly get the information and answers they need on a cost effective basis. If NNBP successfully merge with EUREKA GENOMICS, this will be huge for NNBP. Remember EUREKA GENOMICS is a revenue-producing company that is well positioned to play a defining role in the evolution of high-value diagnostic tests and medicines, as well as clean tech products such as bio-energy feed stocks and bio-based industrial catalysts this is also coupled with the $3.7 million funding already closed early this year. http://www.eurekagenomics.com/hts-bioinformatics_pr.html WEBSITE: http://www.eurekagenomics.com/index.html Just on December 14th, NNBP was reinstated with SOS in Florida. http://www.sunbiz.org/pdf/88665991.pdf This explains to me merger or something big is in the works and it is only a matter of time till we start seeing fillings about this proposed merger. With the stock currently trading at .0054, I believe strongly that this is a buy opportunity before the bombshell. Just a few years ago Wall street resources gave .91 price target on NNBP. NNBP Target Value of $0.91.by Wall Street Resources: http://www.nsti.org/press/PRshow.html?id=1328 and that was before the proposed merger. I wonder how much it will be worth now that they are merging with a company that just closed $3.7 million financing just in March this year. I leave the rest to you to do the math. This DD was brought to you by Harvard Law. |
|
| aus der Diskussion: | | Nanobac Pharm noch investieren ? |
| Autor (Datum des Eintrages): | Imperator7 (03.02.11 20:41:58) |
| Beitrag: | 87 von 93 (ID:40979023) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |